14 Citazioni (Scopus)

Abstract

The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent findings regarding EGFR-inhibition in NSCLC, highlighting the current unsolved questions on the selection of the best TKI in first-line, which therapy can be combined with upfront EGFR-TKIs, how to overcome acquired resistance, and which are the clinical applications of liquid biopsy.
Lingua originaleEnglish
pagine (da-a)126-135
Numero di pagine10
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume112
Stato di pubblicazionePublished - 2017

Fingerprint

Epidermal Growth Factor Receptor
Therapeutics
Platinum
Lung Neoplasms
Biopsy
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cita questo

@article{c8b565dcde35415db14cfc224e95efeb,
title = "EGFR inhibition in NSCLC: New findings…. and opened questions?",
abstract = "The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent findings regarding EGFR-inhibition in NSCLC, highlighting the current unsolved questions on the selection of the best TKI in first-line, which therapy can be combined with upfront EGFR-TKIs, how to overcome acquired resistance, and which are the clinical applications of liquid biopsy.",
keywords = "EGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factor; Hematology; Oncology; Geriatrics and Gerontology",
author = "Angela Listi' and Francesco Passiglia and Alessandro Perez and Viviana Bazan and Antonio Russo and Marta Castiglia and Sergio Rizzo",
year = "2017",
language = "English",
volume = "112",
pages = "126--135",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - EGFR inhibition in NSCLC: New findings…. and opened questions?

AU - Listi', Angela

AU - Passiglia, Francesco

AU - Perez, Alessandro

AU - Bazan, Viviana

AU - Russo, Antonio

AU - Castiglia, Marta

AU - Rizzo, Sergio

PY - 2017

Y1 - 2017

N2 - The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent findings regarding EGFR-inhibition in NSCLC, highlighting the current unsolved questions on the selection of the best TKI in first-line, which therapy can be combined with upfront EGFR-TKIs, how to overcome acquired resistance, and which are the clinical applications of liquid biopsy.

AB - The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent findings regarding EGFR-inhibition in NSCLC, highlighting the current unsolved questions on the selection of the best TKI in first-line, which therapy can be combined with upfront EGFR-TKIs, how to overcome acquired resistance, and which are the clinical applications of liquid biopsy.

KW - EGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor

KW - Epidermal Growth Factor; Hematology; Oncology; Geriatrics and Gerontology

UR - http://hdl.handle.net/10447/234299

UR - http://www.elsevier.com/locate/critrevonc

M3 - Article

VL - 112

SP - 126

EP - 135

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -